Feng Zhang
Chinese–American biochemist
Follow Feng Zhang on Notably News to receive short updates to your email — rarely!
| 2025 | Received the National Medal of Technology and Innovation, jointly with Jennifer Doudna. |
| 2021 | Received the Richard Lounsbery Award. |
| 2019 | Received the Harvey Prize from the Technion/Israel (jointly with Emmanuelle Charpentier and Jennifer Doudna) and the Golden Plate Award from the American Academy of Achievement. |
| 2018 | Elected as a Fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences and National Academy of Medicine. |
| 2018 | Zhang co-founded Sherlock Biosciences to develop the SHERLOCK diagnostic technology for detecting viruses and bacteria. |
| 2018 | Zhang co-founded Beam Therapeutics with David R. Liu to advance base editing and prime editing technologies. |
| 2017 | Received the Albany Medical Center Prize (jointly with Emmanuelle Charpentier, Jennifer Doudna, Luciano Marraffini, and Francisco Mojica) and the Lemelson-MIT Prize. |
| 2016 | Received the Gairdner Foundation International Award and the Tang Prize (both shared with Doudna and Charpentier). Named a laureate of the Asian Scientist 100. |
| 2016 | Zhang discovered Cas13 with Harvard colleague Eugene Koonin using computational biology methods and co-founded Arbor Biotechnologies to develop Cas13 for therapeutic use. |
| 2015 | Became the inaugural recipient of the Tsuneko & Reiji Okazaki Award from Nagoya University. |
| 2014 | Received multiple prestigious awards, including the Alan T. Waterman Award (National Science Foundation's highest honor for researchers under 35), the Gabbay Award (shared with Jennifer Doudna and Emmanuelle Charpentier), and the NYSCF – Robertson Stem Cell Investigator Award. |
| 2013 | Selected as one of MIT Technology Review's TR35, highlighting his innovative technological contributions. |
| September 2013 | Zhang, along with Jennifer Doudna and colleagues from Harvard, founded Editas Medicine to develop and commercialize CRISPR-based therapies. |
| 2012 | Feng Zhang was named a Searle Scholar, recognizing his promising early-career research. |
| 2011 | Zhang began work to optimize the CRISPR system for use in human cells, comparing RNA expression approaches and establishing key features for Cas9 functionality in mammalian cells. |
| 2010 | Optogenetics was named the 'Method of the Year', highlighting Zhang's leadership in the field. |
This contents of the box above is based on material from the Wikipedia article Feng Zhang, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.